Stocks Health care INKT
NASDAQ · Health careMiNK Therapeutics, Inc. (INKT)
It posted a net loss of $11.4M. At June 30, 2026 it held $8.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What MiNK Therapeutics, Inc. does
MiNK Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INKT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$12.5M | -$2.93 | n/a |
| 2024 | n/a | -$10.8M | -$2.86 | n/a |
| 2023 | n/a | -$22.5M | -$6.54 | -$15.8M |
| 2022 | n/a | -$28M | -$8.35 | -$19.1M |
| 2021 | n/a | -$30.2M | -$11.67 | -$13.1M |
| 2021 | n/a | -$16.2M | -$6.74 | -$8.4M |
Latest SEC filings
What MiNK Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
- June 23, 2026
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026
- May 15, 2026
- April 30, 2026
- April 30, 2026Proxy statement DEF 14A
- March 31, 2026Annual report 10-K · period to December 31, 2025
- March 31, 2026
Questions about INKT
What does MiNK Therapeutics, Inc. do?
MiNK Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker INKT.
Is MiNK Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $11.4M.
When did MiNK Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 2, 2026.
Similar companies
Follow INKT
Get an email when MiNK Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow INKT: get an email when it filesWhere the numbers come from
Financial figures are the values MiNK Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.